Inclusion Body Myositis — Research Summary
Printed from RareWays (rareways.com.au) on 11 September 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Diagnostic utility of inflammatory markers in formalin-fixed and paraffin-embedded muscle biopsies for idiopathic inflammatory myopathies.
Suriyonplengsaeng Chinnawut et al. — Histopathology (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42266100/
- 2.
Paradigm shift in the pathomechanisms and treatment of inclusion body myositis: at the crossroads of cell-autonomous muscle degeneration and immune activation.
Suzuki Naoki et al. — Current opinion in neurology (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42615630/
- 3.
Inclusion body myositis: new insights into pathogenesis and therapeutic perspectives.
Fer François et al. — Current opinion in rheumatology (2 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42682173/
- 4.
Monomethylation of cytosolic 5'-nucleotidase 1A affects its recognition by inclusion body myositis autoantibodies.
Brinkman Fleur et al. — Journal of neuromuscular diseases (2 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42684297/
- 5.
Correction to "Muscle Ultrasound in Inclusion Body Myositis: Integrating Qualitative and Quantitative Approaches With Clinical and MRI Findings".
— Muscle & nerve (1 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42487526/
Clinical Trials — Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis
Active (not recruiting) — Phase 2 — Abcuro, Inc.
https://clinicaltrials.gov/study/NCT06450886
- 2.
A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis
Completed — Phase 2 — Abcuro, Inc.
https://clinicaltrials.gov/study/NCT05721573
- 3.
Phase III Trial of Sirolimus in IBM
Active (not recruiting) — Phase 3 — University of Kansas Medical Center
https://clinicaltrials.gov/study/NCT04789070
- 4.
A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)
Completed — Phase 1 — Abcuro, Inc.
https://clinicaltrials.gov/study/NCT04659031
- 5.
An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
Completed — Phase 3 — Novartis Pharmaceuticals
https://clinicaltrials.gov/study/NCT02573467
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Inclusion Body Myositis
Inclusion body myositis is a rare muscle disease that mostly starts after the age of 50. It causes slowly worsening weakness, often first in the thigh muscles and fingers, and can lead to falls and difficulty swallowing. No treatment has yet been proven to stop it, so care focuses on exercise, physiotherapy and managing symptoms while clinical trials continue.
Most Recent Research
OBJECTIVE: This study aimed to develop a reproducible immunohistochemistry method for formalin-fixed, paraffin-embedded (FFPE) muscle sections and to assess its diagnostic utility for idiopathic inflammatory myopathies (IIM) in settings where snap-frozen muscle biopsy is unavailable. METHODS: Twenty cases were analysed: dermatomyositis (n = 5), inclusion body myositis (n = 2), immune-mediated necrotizing myopathy (n = 5), overlap myositis (n = 1), unspecified myopathy (n = 3), mitochondrial myopathy (n = 1), LGMD R2 dysferlin-related muscular dystrophy (n = 1), facioscapulohumeral muscular dystrophy (n = 1), and neurogenic muscle change (n = 1). Immunohistochemistry was performed on 3-μm FFPE muscle sections using heat-induced antigen retrieval with citrate/EDTA buffer and overnight incubation at 4°C with antibodies against MHC-I, MHC-II, MAC, MxA, and p62. Frozen sections were analysed in parallel for comparison. RESULTS: Comparable staining intensities and patterns for MHC-II, MxA, and p62 were achieved in FFPE muscle sections. Although discrepancies between frozen and FFPE sections occurred in eight cases, each involving a single marker, no statistically significant differences in immunohistochemical results were observed for MHC-II (P = 0.4795), MxA (P = 0.4795), and p62 (P = 0.6171). Concordance between methods was high, reaching 90% for MHC-II and MxA and 80% for p62. These isolated discrepancies may reflect variability in antigen expression associated with the segmental and patchy involvement characteristic of IIM. However, MHC-I and MAC staining were unsuccessful in FFPE sections. CONCLUSIONS: Successful immunolabelling of MHC-II, MxA, and p62 was achieved in FFPE muscle sections. These findings indicate that several diagnostically informative markers for IIM can be reliably assessed in FFPE muscle, providing a practical diagnostic option in resource-constrained settings.
Common Questions
What is Inclusion Body Myositis?
Inclusion body myositis is a rare muscle disease that mostly starts after the age of 50. It causes slowly worsening weakness, often first in the thigh muscles and fingers, and can lead to falls and difficulty swallowing. No treatment has yet been proven to stop it, so care focuses on exercise, physiotherapy and managing symptoms while clinical trials continue.
How many clinical trials are available for Inclusion Body Myositis?
RareWays currently indexes 42 clinical trials for Inclusion Body Myositis, of which 5 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Inclusion Body Myositis come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Inclusion Body Myositis.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.